Supplement to the prospectus relating to the invitation to subscribe for shares in Oncology Venture Sweden AB

About the supplementary prospectus

This prospectus supplement is a supplement to the prospectus relating to the offer to subscribe for shares in Oncology Venture Sweden AB, which has been prepared by the Board of Oncology Venture Sweden AB ("Oncology Venture"), corporate registration number 559016-3290. The company conducts a rights issue with subscription period January 11th – January 25th, 2018. The public is also given the opportunity to subscribe for shares in the rights issue. The Prospectus was approved and registered by the Swedish Financial Supervisory on January 4th, 2018. Financial Supervisory registration number is 17-20723. The prospectus was published on January 4th, 2018 and is available on the company's and AktieTorget´s websites (www.oncologyventure.com and www.aktietorget.se).

The supplementary prospectus is a part of and should be read as part of the prospectus. The supplementary prospectus has been prepared in accordance with Chapter 2. 34 § The Act (1991: 980) regarding trading with financial instruments ("FITA") and was on January 22nd, 2018 approved and registered by the Swedish Financial Supervisory Authority. Financial Supervisory registration number of the prospectus supplement is 18-1257. Date of publication of the prospectus supplement is January 22nd, 2018.

This supplementary prospectus has been prepared due to:

- Oncology Venture, on January 15th, 2018, after that the Financial Supervisory Authority approved Oncology Venture's prospectus, issued a press release that disclosed initial conclusions from a study of the DRP of a phase 3 TKI product from Big Pharma: in the study of data from renal cancer patients' biopsies - where the DRP score was compared with the outcome of clinical trial results - a consistent result was found. Based on this, the Company's goal is to develop the drug and it's DRP to commercial success.

The additional information is added in Oncology Ventures prospectus on the following pages:

Page 5, B.3 "Aktiviteter"

The following sentence in the third paragraph under B.3 is replaced in the prospectus: The sentence "OV-SPV2 ApS har indlicenseret en TKI-hæmmer fra Big Pharma-virksomheden Novartis Pharma AG til behandling af kræft ved hjælp af DRP® og Selskabet har endelig mulighed for at indlicensere produktet, når DRP® har valideret dette. OV-SPV2 ApS vil gennemføre en hurtig test af egnetheden af DRP® og afhængigt af resultat ansøge som "end of phase 2"-møde med FDA om TKI-hæmmeren." is replaced with "OV-SPV2 ApS har indlicenseret en TKI-hæmmer fra Big Pharma-virksomheden Novartis Pharma AG til behandling af kræft ved hjælp af DRP® og Selskabet har valgt at bruge licensoptionen for TKI-hæmmeren som følge af de oprindelige data præsenteret i januar 2018."

Page 20, "Oncology Venture has recently made great strides by having…"

The following bullet point is added on the bottom of the bullet list:

- Announced initial conclusions from a study of the DRP® concerning the TKI product from Novartis, which showed a consistent result.

Page 21, "A few comments from CEO Peter Buhl Jensen"

The following sentences in the prospectus' CEO letter (row 7-11 in paragraph 2) is replaced with the information below: " The first part gives permission to test in advance if DRP® is able to identify which patients may benefit from treatment with TKI in a Phase 3 clinical trial in renal cancer. Biopsy data from 150 patients from the study will be analyzed with our DRP® technology and blindly predict which of the patients it was who showed efficacy from the drug. If DRP ® can accomplish this, our intention would naturally be to enter into the second part of the agreement, due to us having an exceptional risk reduced opportunity to develop effective cancer treatments." is replaced with "The first part gave us permission to test in advance if DRP® is able to identify which patients may benefit from treatment with TKI in a Phase 3 clinical trial in renal cancer. Biopsy data from 150 patients from the study was analyzed with our DRP® technology and the initial conclusions show a consistent result. We have therefore chosen to execute the license option concerning the TKI product and the TKI product will be the strongest and most advanced in Oncology Venture's pipeline with clear efficacy in several cancers. I am confident that we can develop the TKI to commercialisation and once we have the full data package in-house we can further develop the DRP to a useful tool for clinical guidance to foresee patients' benefit of the drug."

Page 22, under "Prioritized activities"
Current sentence in the first paragraph (row 1) is added: After the sentence "If the TKI data is positive, both products will be successfully predicted by DRP and thus be significantly risk-reducing." the following sentence is added "Oncology Venture announced in January 2018 that initial data from the DRP® study with the TKI product showed that a consistent signal could be identified concerning the TKI-DRP's ability to predict clinical benefit in the phase 3 study with the TKI product in renal cancer patients."

Current sentences in the first paragraph (row 8-10) are replaced with the following: "According to a schedule, Oncology Venture will publish data from the analysis of biopsies from the Novartis TKI study of renal cancer, in the third week of January 2018. If the data shows positive signs, this will be the most advanced product in the pipeline and will have the potential to lead to an "End of Phase 2" at the FDA meeting." are replaced with "Oncology Venture announced in January 2018 that initial conclusions from the DRP® study with the TKI product showed consistent results. Several parameters were evaluated in this blinded study and though some were not statistically significant, others were, and a consistent signal was seen of the TKI DRP's ability to foresee clinical benefit in the phase 3 TKI trial in renal cancer patients. Based on this, the company's ambition is now to develop the drug and its DRP® to clinical success. The TKI product is this the most advanced product the company's pipeline and the product has the potential to lead to an "End of Phase 2" at a FDA meeting."

Page 23, under "TKI"
Under the section "Activity commenced", the following sentence is replaced: The sentences "Oncology Venture is currently awaiting data from biopsies from Novartis, which is expected to become available in the third week of January 2018. At this point, the Company will know if DRP can predict respondents, after which Oncology Venture will initiate talks with the U.S. Food and Drug Administration (FDA) regarding an end-of-phase 2 meeting request, and then the Company can communicate the future regarding the TKI inhibitor." are replaced with "Initial conclusions from the DRP® study with the TKI product showed a consistent result. Several parameters were evaluated in this blinded study and though some were not statistically significant, others were, and a consistent signal was seen of the TKI DRP's ability to foresee clinical benefit in the phase 3 TKI trial in renal cancer patients."

Under the section "Ownership" the following sentence is added in the end under "TKI": "Oncology Venture announced in January 2018 that the board had decided to execute the TKI license."

Page 32, under "TKI (OV-SPV2 ApS)"
The following sentences are replaced in the prospectus: The sentences "Oncology Venture has the possibility to implement an accelerated DRP® test on available patient biopsies, in order to assess whether the DRP® tool can identify respondents from the clinical trials." are replaced with "Oncology Venture has conducted an accelerated DRP® test in order to assess whether the DRP® tool can identify respondents from the clinical trials. In the study of data from renal cancer patients' biopsies - where the DRP score was compared with the outcome of clinical trial results - a consistent result was found. Based on this, the company's goal is to develop the drug and it's DRP to commercial success. Several parameters were evaluated in this blinded study and though some were not statistically significant, others were, and a consistent signal was seen of the TKI DRP's ability to foresee clinical benefit in the phase 3 TKI trial in renal cancer patients. Oncology Venture has decided to execute the TKI license - which terms have already been negotiated."

Page 36, under "OV-SPV2 ApS"
The following sentences are replaced in the prospectus: The sentences " Oncology Venture is currently conducting an accelerated DRP® test on available patient biopsies in order to assess if the DRP® tool is able to identify respondents from the clinical trials. The project is financially a high-risk project, and is therefore kept separate so as not to affect Oncology Venture if the results are not shown to be positive, but the Board of Directors of Oncology Venture considers this to be a unique opportunity to implement a risk-reduced development program of the tyrosine kinase inhibitor if the unique tyrosine kinase inhibitor's DRP® works. Oncology Venture will sublicense its rights to use the DRP® to OV-SPV2." are replaced with " Oncology Venture has conducted an accelerated DRP® test in order to assess whether the DRP® tool can identify respondents from the clinical trials. In the study of data from renal cancer patients' biopsies - where the DRP score was compared with the outcome of clinical trial results - a consistent result was found. Based on this, the company's goal is to develop the drug and it's DRP to commercial success. Several parameters were evaluated in this blinded study and though some were not statistically significant, others were, and a consistent signal was seen of the TKI DRP's ability to foresee clinical benefit in the phase 3 TKI trial in renal cancer patients."

The following sentence is added to the prospectus: After the sentence ” If the results from the initial DRP analysis show positive results, Oncology Venture intends to co-invest and bring this promising medicine in the Company’s pipeline.”, the following sentence is added ” Oncology Venture has decided to execute the TKI license - which terms have already been negotiated.”

Right to withdraw

Investors who before the publication of the supplement prospectus, has subscribed for shares in the ongoing rights issue as described in the prospectus, in accordance with Chapter 2. 34 § Trading Act, have the right to withdraw their subscription of shares within two working days of publication of this prospectus, that is, by January 24th, 2018. Timing or terms and conditions are not affected of this prospectus supplement.

Delivery of the prospectus supplement

The Board of Oncology Venture Sweden AB hereby delivers prospectus supplement. Supplementary prospectus is available on the company's and AktieTorget´s websites (www.oncologyventure.com and www.aktietorget.se).

Hørsholm, January 22nd, 2018
The Board of Oncology Venture Sweden AB

Duncan Moore – Chairman of the Board
Sanjeevi Carani – Board Member
Steen Knudsen – Board Member
Ulla Hald Buhl – Board Member
Peter Birk – Board Member